We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
Cap. Flow
-$8.88M
Cap. Flow %
-0.86%
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$21.3M
2
ANGO icon
AngioDynamics
ANGO
+$13.9M
3
XENT
Intersect ENT, Inc
XENT
+$11.1M
4
MDCO
Medicines Co
MDCO
+$9.01M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.81M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$18.7M
2
XNPT
XENOPORT, INC.
XNPT
+$7.18M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$6.39M
4
ELOS
Syneron Medical Ltd
ELOS
+$6.36M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$5.34M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTX
76
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-609,083
Closed -$6.39M
XNPT
77
DELISTED
XENOPORT, INC.
XNPT
– –
-1,592,067
Closed -$7.18M
CRDC
78
DELISTED
CARDICA INC COM NEW (DE)
CRDC
– –
-887,499
Closed -$3.16M
EPRS
79
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
– –
-1,079,543
Closed -$2.9M
ANAC
80
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-400,000
Closed -$21.4M
ANAC
81
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-100,000
Closed -$5.34M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital's Q2 2016 filing shows 13 new, 14 increased, 14 reduced and 14 closed positions. Its largest new stake was Endo International plc: 1,028,802 shares worth $16M. The largest sale was NEVRO CORP., an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 71% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2016 buy was Endo International plc: 1,028,802 shares worth $16M.
  • Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
  • Broadfin Capital's biggest Q2 2016 reduction was NEVRO CORP., cutting an estimated $18.7M.
  • Broadfin Capital fully exited XENOPORT, INC. in Q2 2016, selling an estimated $7.18M.
  • Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
  • Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.